The negative prognostic impact of bone metastasis with a tumor mass

OBJECTIVE: Typically, bone metastasis causes osteolytic and osteoblastic lesions resulting from the interactions of tumor cells with osteoclasts and osteoblasts. In addition to these interactions, tumor tissues may grow inside bones and cause mass lesions. In the present study, we aimed to demonstrate the negative impact of a tumor mass in a large cohort of patients with bone metastatic cancer. METHODS: Data from 335 patients with bone metastases were retrospectively reviewed. For the analysis, all patients were divided into three subgroups with respect to the type of bone metastasis: osteolytic, osteoblastic, or mixed. The patients were subsequently categorized as having bone metastasis with or without a tumor mass, and statistically significant differences in median survival and 2-year overall survival were observed between these patients (the median survival and 2-year overall survival were respectively 3 months and 16% in patients with a tumor mass and 11 months and 26% in patients without a tumor mass;

DNA Repair Gene Polymorphisms In B Cell Non-Hodgkin’s Lymphoma.

TEZ9344Tez (Uzmanlık) -- Çukurova Üniversitesi, Adana, 2011.Kaynakça (s. 49-55) var.x, 56 s. : res. (bzs. rnk.), tablo ; 29 cm.Kanser, DNA’da hasarların sık olduğu hastalıklar grubudur. Kanserlerin etyolojisinde çevresel ve genetik faktörlerin çok önemli olduğu tartışılmaz bir gerçektir. Genel popülasyonda DNA onarım kapasitesindeki değişkenliklerle kanserlere duyarlılık arasında ilişki saptanmıştır. Ulaşılabilen literatürde ülkemizde erişkin NHL ile DNA onarım gen polimorfizmleri arasındaki ilişkiyi araştıran herhangi bir çalışmaya rastlanmamıştır. Daha önceki çalışmalarda lenfoma görülme yaşının, batı ülkeleriyle kıyaslandığında 10 yıl kadar daha genç yaşta görüldüğü gösterilmiştir. Çalışmamızın amacı, bu erken yaş gözlemi nedeniyle kişinin DNA hasarına verdiği yanıtın belirlenmesinde çok önemli olan DNA onarım genlerindeki tek nükleotid polimorfizmleri ile lenfomalar arasındaki ilişkiyi araştırmaktı. Çalışmaya 94 B hücreli NHL tanılı hasta ve 96 sağlıklı kontrol grubu dahil edildi. Hastaların 60’ı (%63,8) DBBHL, 13’ü (%13,8) folliküler lenfoma, 6’sı (%6,4) küçük lenfositik lenfoma, 6’sı (%6,4) marjinal zon lenfoma ve 9’u (%9,6) diğer lenfoma tanısı olan hastalardı. Hastaların 49’u (%52,1) erkek, 45’i (%47,9) kadın hastalardı. Hasta ve kontrol gruplarında ERCC2 (Lys751Gln), XPC (Gln939Lys), ERCC5 (Asp1104His) ve XRCC3 (Thr241Met) gen polimorfizmleri çalışıldı. Çalışılması planlanan XRCC1 Arg399Gln gen polimorfizmi, teknik nedenlerden ve yeterli finansman sağlanamamasından dolayı çalışılamadı. ERCC5 Asp1104His polimorfizminin, kontrol grubunda daha fazla saptanması nedeniyle mutant aleli taşıyan bireylerde hastalıktan koruyucu etki gösterebileceği düşünüldü (p=0,009). Bu anlamlı fark erkek cinsiyette daha belirgin bulundu (p=0,001). Hasta ve kontrol grupları, sigara içen ve içmeyen diye gruplara ayrıldığında; sigara içmeyen grupta XPC geni mutant alelinin hastalıktan koruyucu etki gösterdiği saptandı (p=0,040). NHL olguları ve kontrol grupları arasında ERCC2 kodon 751, XPC kodon 939 ve XRCC3 kodon 241 gen polimorfizmleri açısından istatistiksel olarak anlamlı bir fark saptanmadı (p>0,05). Çalışılan 4 gen polimorfizmi için mutant aleli içeren ve içermeyen gruplar karşılaştırıldığında, ERCC5 CG polimorfizminin G mutant alelini içeren bireylerde, G mutant alelini içermeyen bireylere göre hastalıktan koruyucu etki gösterdiği saptandı (p=0,010). Sonuç olarak; DNA onarım gen polimorfizmleri lenfoma riskinde etkili olabilir. Bu nedenle toplumumuzda görece sık görülen lenfomalarda DNA onarım genlerindeki polimorfizmlerin belirlenmesi, lenfomagenezdeki katkısını anlamada yararlı olabilir.Cancer is a group of diseases characterized by frequent DNA injury. Genetic and environmental factors are very important in the etiology of the cancers. It has been detected an association between variabilities in DNA repair capacity and sensitivity to the cancer. We did not find a study about DNA repair gene polymorphism in adult lymphoma cases in our country. In some previous studies, it has been found that NHLin our country is seen 10 years younger than western countries. The aim of our study is to investigate DNA repair gene single nucleotide polymorphisms in B cell NHL. Ninety four casses with NHL and 96 healthy controls were included in this study 60 of the cases (%63,8) had DLBCL, 13 cases (%13,8) had follicular lymphoma, 6 cases (%6,4) had small lymphocytic lymphoma, 6 cases (%6,4) had marginal zone lymphoma and 9 cases (%9,6) had other type of B cell lymphomas. Male/female ratio was 49/45. ERCC2 (Lys751Gln), XPC (Gln939Lys), ERCC5 (Asp1104His) and XRCC3 (Thr241Met) gene polymorphisms were studied in the cases and control groups. Study of XRCC1 Arg399Gln gene polymorphism was planned, but could not be studied due to technical reasons and insufficient funding. ERCC5 Asp1104His polymorphism showed a protective effect against the disease in individuals carrying the mutant allele (p=0,009). This difference was found to be more pronounced in males (p=0,001). The patient and control groups were divided as smoker and nonsmoker and in nonsmoker group, the mutant allele of XPC gene showed protective effect (p=0,040). ERCC2 codon 751, XPC codon 939 and XRCC3 codon 241 gene polymorphisms were not found to be different between cases with NHL and controls (p>0,05). The mutant allele G of ERCC5 (CG) polymorphism in individuals with the G mutant allele as compared with controls showed a protective effect (p=0,010). In conclusion DNA repair gene polymorphisms may affect the risk of lymphoma. Therefore, it will be useful to detect the DNA repair gene polymorphism in cases with lymphoma which is relatively frequent neoplasia in our country.Bu çalışma Ç.Ü. Bilimsel Araştırma Projeleri Birimi tarafından desteklenmiştir. Proje No: TF2010LTP24

The Prognostic Value Of Uhrf-1 And P53 In Gastric Cancer

Background/Aims: This study aimed to examine whether UHRF-1 and p53 overexpression is a prognostic marker for gastric cancer. Patients and Methods: Sixty-four patients with gastric cancer (study group) and 23 patients with gastritis (control group) were evaluated. Immunohistochemistry was used to examine expression of UHRF-1 and p53 in gastric cancers and a control group diagnosed with gastritis. Results: The median age was 63 years (18-83 years) in the study group. UHRF-1 was positive in 15 (23%) patients with gastric cancer and five (21.7%) patients with gastritis (P = 0.559). UHRF1 expression level in gastric cancer is more powerful than in gastritis (P = 0.046). Thirty-seven (61%) patients with gastric cancer and only one patient with gastritis were p53 positive (P < 0.001). After a median follow-up of 12 months (1–110), the 2-year overall survival rates were 55% and 30% in negative and positive p53, respectively (P = 0.084). Also, the 2-year overall survival rates were 45% and 53% in negative and positive UHRF-1, respectively (P = 0.132). Conclusion: According to this study, UHRF-1and p53 were not prognostic factors for gastric cancer, whereas they may have a diagnostic value for differantiating between gastric cancer and gastritis.PubMedWoSScopu

XELOX Plus Bevacizumab vs. FOLFIRI Plus Bevacizumab Treatment for First-line Chemotherapy in Metastatic Colon Cancer: a Retrospective Study of the Anatolian Society of Medical Oncology

Background: XELOX plus bevacizumab (XELOX-Bev) and FOLFIRI plus Bevacizumab (FOLFIRI - Bev) treatments are an effective strategies patients with metastatic colorectal cancer (mCRC). The aim of this study was to compare efficacy of first-line XELOX-Bev treatment vs FOLFIRI-Bev treatment for mCRC. Materials and Methods: A total of 409 patients with mCRC who received chemotherapy were included and divided into 2 groups. Group 1 (n=298) received XELOX-Bev and Group 2 (n=111) FOLFIRI-Bev. Comparisons were made in terms of overall (OS) and progression-free (PFS) survival, response rate (RR), and grade 3-4 toxicity. Results: Median follow-up was 11 months in Group 1 and 15 months for Group 2. Complete remission was observed in 29 (9.7%) and 2 (1.8%) patients, partial remission in 139 (46.6%) and 27 (24.5%), stable disease in 88 (29.5%) and 49 (44.1%) and progressive disease in 42 (14.1%) and 33 (30.0%) patients in Group 1 and 2, respectively. Median OS was 25 months (range 2-57 months, 95% CI; 22.2-27.7) for Group 1 and 20 months (range 1-67 months, 95% CI; 16.8-23.1) for Group 2 (p=0.036). Median PFS was 9.6 months (range 2-36 months, 95% CI; 8.8-10.4) for Group 1 and 9 months (range 1-44 months, 95% CI; 7.4-10.5) for Group 2 (p=0.019). Objective RR was 56.4% in Group 1 and 26.1% in Group 2 (p<0.001). Conclusions: First-line XELOX-Bev is more effective with a better response rate, prolongation of median PFS/OS, and a superior safety profile compared with FOLFIRI-Bev

Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group

Aims: The addition of aflibercept to the fluorouracil and irinotecan (FOLFIRI) regimen significantly improved clinical outcomes in patients with metastatic colorectal cancer (CRC) previously treated with oxaliplatin. We aimed to investigate the efficacy and safety of second-line FOLFIRI and aflibercept combination in patients with metastatic CRC in real-life experience. Materials and Methods: Four hundred and thirty-three patients who treated with FOLFIRI and aflibercept in the second-line were included in the study. The clinical and pathological features of the patients were recorded retrospectively. Survival (overall and progression-free survival [PFS]), response rates, and safety data were analyzed. Results: The median age was 61. Majority of patients (87.5%) received first-line bevacizumab and 10.1% of patients received anti-epidermal growth factor receptor agents. About 80% of patients had KRAS, 18.6% of patients had NRAS, and 6.4% of patients had BRAF mutations. The median OS was 11.6 months (95% confidence interval [CI], 10.6-12.6) and the median PFS was 6 months (95% CI, 5.5-6.5). About 4.6% of patients had complete response and 30.6% of patients had partial response as best tumor response. Grade 1-2 toxicities were seen in 33.4% of patients, while grade 3-4 toxicities were recorded in 27% of patients. Eight patients (2%) died due to treatment toxicity. Conclusions: Overall and PFS were similar in routine clinical practice compared to phase III pivotal VELOUR trial. However, response rates were found to be higher. It was observed that there were fewer adverse events compared to the VELOUR trial

The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: A Turkish Oncology Group Study

Introduction Osimertinib, an irreversible third-generation EGFR-TKI, is the standard of care for second-line treatment of T790M-mutant advanced NSCLC patients whose disease progressed after first-line EGFR-TKI therapy. In this multicenter study, we aimed to determine the real-life efficacy and safety of Osimertinib in pretreated advanced NSCLC patients with T790M mutation. Materials and methods This retrospective trial included advanced T790M-mutant pretreated NSCLC patients who received Osimertinib from 24 different centers in Turkey. Primary endpoint was time-to-treatment discontinuation (TTD). Secondary endpoints were objective response rate (ORR), overall survival (OS), and safety. Results Of 163 patients, 68.7% had EGFR exon 19 deletion and 22.7% had exon 21 L858R mutation. Osimertinib was given as second-line treatment in 96 patients (58.9%) and third-line in 48 patients (29.4%). After median of 13-month follow-up, median TTD was 21.6 months with an 82.2% ORR. Estimated median OS was 32.1 months. Grade 3-4 adverse events were seen in 11.7% of the patients. Conclusion Osimertinib is a highly effective option in second- or third-line treatment of NSCLC patients with T790M mutation, with a favorable safety profile

Does primary tumor localization has prognostic importance in seminoma patients?: Turkish Oncology Group Study

Purpose: The purpose of this study was to determine whether primary tumor localization may be a risk factor for relapse and survival in seminomatous germ cell tumors (GCT) patients.Methods: In our study, 612 seminomatous GCT patients diagnosed in 22 centers between 01.01.1989 and 03.02.2019 were retrospectively evaluated. Patient interview information, patient files and electronic system data were used for the study.Results: The primary tumor was localized in the right testis in 305 (49.9%) patients and in 307 (50.1%) in the left testis. Mean age of the patients was 36 years (range 16-85 +/- 10.4).The median follow-up period was 47 months (1-298). Recurrence was observed in 78 (127%) patients and 29 (4.7%) died during the follow-up period. Four-year overall survival (OS) was 95.4% and 4-year progression-free survival (PFS) was 84.5%. The relationship between localization and relapse was significant in 197 patients with stage 2 and stage 3 (p=0.003). In this patient group, 41 (20.8%) relapses were observed. Thirty (73.2%) of the relapses were in the right testis and 11 (26.8%) in the left testis.Four-year OS was 92.1% in patients with right tumor; and 98.7% in patients with left tumor (p=0.007). When 612 patients were evaluated with a mean follow-up of 4 years, there was a 6.6% survival advantage in patients with left testicular tumor and this difference was significant (p=0.007).Conclusion: Survival rates of patients with primary right testicular localization were worse compared with left testicular localization, and relapse rates were higher in stage 2 and 3 patients with right testicular localization